New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:34 EDTRGEN, BMRNRepligen announces asset purchase agreement with BioMarin for HDACi Portfolio
Repligen (RGEN) announced that it has entered into an asset purchase agreement with BioMarin Pharmaceutical (BMRN) to advance Repligen's histone deacetylase inhibitor, or HDACi, portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Under the terms of the agreement, Repligen will receive an upfront payment of $2M from BioMarin and it has the potential to receive up to $160M in future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. Potential applications of the HDACi portfolio include Friedreich's ataxia and other neurological disorders.
News For RGEN;BMRN From The Last 14 Days
Check below for free stories on RGEN;BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
12:18 EDTBMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
September 17, 2014
07:43 EDTBMRNBofA/Merrill to hold a conference
Subscribe for More Information
September 8, 2014
07:15 EDTBMRNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use